References
- Juweid M E, Wiseman G A, Vose J M, Ritchie J M, Menda Y, Wooldridge J E, et al. Response assessment of aggressive non-Hodgkin's lymphoma by Integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005; 23: 4652–4661
- Maloney D G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005; 23: 6421–6428
- Baudard M, Comte F, Conge A M, Mariano-Goulart D, Klein B, Rossi J F. Importance of [18F] fluorodeoxyglucose-positron emission tomography scanning for the monitoring of responses to immunotherapy in follicular lymphoma. Leuk Lymphoma 2007; 48: 381–388
- Freudenberg L S, Antoch G, Schutt P, Beyer T, Jentzen W, Muller S P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325–329
- Ridolfi R, Riccobon A, Galassi R, Giorgetti G, Petrini M, Fiammenghi L, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004; 2: 27
- Weiner G, Wiseman G, Witzig T, Link B, Wooldridge J, Ponto J, et al. Imaging of peripheral blood mononuclear cells (PBMC) trafficking in patients with non-Hodgkin's lymphoma (NHL) prior to and following therapy. ASH Annual Meeting Abstracts. Blood (Supplement) 2005; 106: 2823